- ►nih.gov U Chakravarthy, G Soubrane, F Bandello, V Chong, … - British Medical …, 2006 - bjo.bmj.com Background: Until recently, only two options were available for the treatment of choroidal neovascularisation
(CNV) associated with age related macular degeneration (AMD)—thermal laser photocoagulation
and photodynamic therapy with verteporfin (PDT-V). However, new treatments for CNV ... Cited by 47 - Related articles - BL Direct - All 11 versions
- ►adisonline.com [PDF] J Wickens, KJ Blinder - Drug safety, 2006 - ingentaconnect.com The prevalence of neovascular age-related macular degeneration (AMD) is Abstract expected
to increase significantly during the next 20 years. New treatment alternatives to laser photocoagulation
are on the horizon – the first of these, photodynamic therapy (PDT) with verteporfin, was ... Cited by 10 - Related articles - BL Direct - All 6 versions
PK Kaiser - American journal of ophthalmology, 2006 - Elsevier To provide an overview of angiogenesis and vascular endothelial growth factor (VEGF) and discusses
the development approach, safety, and efficacy results of current and emerging anti-VEGF therapies
for ocular diseases. ... Analysis of literature and current clinical trials of antiangiogenic ... Cited by 51 - Related articles - All 14 versions
PJ Rosenfeld - American journal of ophthalmology, 2006 - Elsevier The use of intravitreal Avastin (bevacizumab, Genentech, Inc, South San Francisco,
California, USA) for the treatment of chorioretinal diseases mediated by vascular endothelial
growth factor (VEGF) has spread throughout the globe in less than six months from the ... Cited by 59 - Related articles - All 14 versions
VR Participants - Retina, 2005 - journals.lww.com Guidelines originally were published in 2002 based on best available scientific data as well as
consensus of expert opinion in the absence of controlled clinical trial data to assist ophthalmologists
with selection of patients for whom photodynamic ther- apy with verteporfin (Visudyne, ... Cited by 89 - Related articles
J Bradley, M Ju, GS Robinson - Angiogenesis, 2007 - Springer Abstract The growth of inappropriately regulated, leaky blood vessels is a prominent component
of sev- eral debilitating eye diseases, such as age-related macular degeneration (AMD), proliferative
diabetic retinopathy (PDR), and retinopathy of prematurity (ROP). New pharmacological ... Cited by 37 - Related articles - BL Direct - All 3 versions
S Sivaprasad, GM Saleh, H Jackson - Eye, 2005 - nature.com Photodynamic therapy (PDT) is a new evidence-based treatment modality available for choroidal
neovascularisation (CNV) secondary to age-related macular degeneratin (AMD). Eligibility for
PDT is based on the morphological classification of the neovascular complex, the benefit ... Cited by 14 - Related articles - BL Direct - All 5 versions
- ►duanessolution.com F Parmeggiani, C Costagliola, D Gemmati, S … - Pharmacogenetics …, 2007 - journals.lww.com Page 1. Original article 1039 Predictive role of coagulation-balance gene polymorphisms
in the efficacy of photodynamic therapy with verteporfin for classic choroidal
neovascularization secondary to age-related macular degeneration ... Cited by 3 - Related articles - BL Direct - All 8 versions
F Parmeggiani, C Costagliola, C Incorvaia, C Campa, … - Ophthalmology, 2006 - Elsevier In the course of our routine clinical practice, we have observed only one case of ASVD after photodynamic
therapy, with poor visual outcome. This adverse event occurred in a 68-year-old white woman
suffering from AMD and subfoveal occult choroidal neovascularization with a minimal ... Cited by 4 - Related articles - All 10 versions
